The Landmarks of OncoPharm series returns to discuss 2 pivotal trials that ushered in the age of aprepitant and NK-1 receptor anagonists for CINV.
Aprepitant in HEC: https://ascopubs.org/doi/pdf/10.1200/JCO.2003.01.095
Aprepitant in MEC: https://ascopubs.org/doi/pdf/10.1200/JCO.2005.09.050
